Rapid Micro Biosystems (NASDAQ:RPID) Posts Earnings Results, Misses Expectations By $0.06 EPS

Rapid Micro Biosystems (NASDAQ:RPID) released its quarterly earnings results on Wednesday. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.06), Zacks reports. Rapid Micro Biosystems had a negative net margin of 140.30% and a negative return on equity of 95.40%. The business had revenue of $8.00 million during the quarter, compared to analyst estimates of $7.60 million.

Here are the key takeaways from Rapid Micro Biosystems’ conference call:

• Revenue and placements improved. Q1 revenue rose 11% year over year to $8 million, driven by 6 Growth Direct system placements, record consumables growth, and stronger recurring revenue, which reached 63% of total revenue.
• Gross margin is improving and expected to keep rising. First-quarter gross margin was 5%, up 8 points from Q4 2025, and management expects positive product gross margin in Q2 with full-year gross margin around 20% and a mid-20% exit rate in Q4.
• MilliporeSigma partnership is expanding the opportunity. Management said the collaboration is broadening placement opportunities, adding exclusive validation/maintenance services for MilliporeSigma-sold systems, and could also support future sourcing and supply agreement benefits.
• Demand pipeline appears healthy, especially in Asia and large accounts. The company highlighted strong engagement with large biopharma customers, first-system placement in China, and growing interest in enterprise-wide automation across the Asia-Pacific region.
• 2026 guidance was reaffirmed despite a larger Q1 loss and cash usage. Rapid Micro maintained full-year revenue guidance of $37 million-$41 million and 30-38 system placements, while Q1 net loss widened to $14.3 million and cash fell to $23 million, though management said liquidity remains supported by a $25 million credit facility.

Rapid Micro Biosystems Price Performance

RPID traded down $0.10 during trading on Wednesday, hitting $2.48. 135,126 shares of the stock traded hands, compared to its average volume of 239,119. Rapid Micro Biosystems has a twelve month low of $2.01 and a twelve month high of $4.94. The company has a market cap of $112.74 million, a price-to-earnings ratio of -2.32 and a beta of 1.52. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.31 and a quick ratio of 2.36. The business has a 50 day moving average price of $2.70 and a 200 day moving average price of $3.35.

Insider Buying and Selling at Rapid Micro Biosystems

In other news, CEO Robert G. Jr. Spignesi sold 38,327 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $3.89, for a total transaction of $149,092.03. Following the completion of the transaction, the chief executive officer directly owned 1,187,770 shares in the company, valued at approximately $4,620,425.30. This represents a 3.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Sean M. Wirtjes sold 17,254 shares of the company’s stock in a transaction on Friday, February 20th. The stock was sold at an average price of $3.92, for a total transaction of $67,635.68. Following the transaction, the chief financial officer owned 563,674 shares of the company’s stock, valued at $2,209,602.08. This trade represents a 2.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 95,989 shares of company stock worth $385,365 over the last three months. Corporate insiders own 12.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its holdings in shares of Rapid Micro Biosystems by 1.6% during the second quarter. Geode Capital Management LLC now owns 204,079 shares of the company’s stock worth $704,000 after buying an additional 3,143 shares in the last quarter. American Century Companies Inc. increased its holdings in shares of Rapid Micro Biosystems by 46.1% during the second quarter. American Century Companies Inc. now owns 16,922 shares of the company’s stock worth $58,000 after buying an additional 5,341 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Rapid Micro Biosystems by 4.9% during the fourth quarter. Renaissance Technologies LLC now owns 115,627 shares of the company’s stock worth $335,000 after buying an additional 5,440 shares in the last quarter. Susquehanna International Group LLP increased its holdings in shares of Rapid Micro Biosystems by 12.6% during the third quarter. Susquehanna International Group LLP now owns 58,387 shares of the company’s stock worth $195,000 after buying an additional 6,528 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Rapid Micro Biosystems by 37.8% during the third quarter. Dimensional Fund Advisors LP now owns 55,642 shares of the company’s stock worth $186,000 after buying an additional 15,255 shares in the last quarter. 52.60% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research report on Tuesday, April 21st. Wall Street Zen downgraded shares of Rapid Micro Biosystems from a “hold” rating to a “sell” rating in a research report on Saturday. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Rapid Micro Biosystems has an average rating of “Hold” and an average target price of $8.00.

About Rapid Micro Biosystems

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.